Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — H1 2007 Earnings Presentation
22 slides from Novo Nordisk A/s Class B's earnings presentation, Aug 3, 2007
Slide 1: A focused healthcare company
Conference call 3 August 2007 A focused healthcare company First six months of 2007 conference call 3 August 2007, 13.00 CET, 12.00 UK time, 7.00 New York time
Slide 2: Agenda
Conference call 3 August 2007 First six months of 2007 Slide no 1 Agenda • Introduction (Lars Rebien Sørensen, CEO) • Sales update (Lars Rebien Sørensen, CEO) • Pipeline update (Mads Krogsgaard Thomsen, CSO) • Financial results (Jesper Brandgaard, CFO) • Outlook for 2007 (Jesper Brandgaard, CFO) • Q
Slide 3: Forward-looking statements
Conference call 3 August 2007 First six months of 2007 Slide no 2 Forward-looking statements The above contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. This in particular relates to information included under the headings ‘Outlook
Slide 4: Highlights
Conference call 3 August 2007 First six months of 2007 Slide no 3 Highlights Sales development: • Sales of modern insulins increased by 37% (31% as reported) • Sales of NovoSeven® increased by 11% (5% as reported) • Sales of Norditropin® increased by 13% (7% as reported) • Sales in North America inc
Slide 5: Growth in Novo Nordisk's insulin franchise looks set to continue
Conference call 3 August 2007 First six months of 2007 Slide no 4 Growth in Novo Nordisk’s insulin franchise looks set to continue IMS developed world insulin Rapid increase in number of market growth people with diabetes Volume: 5.4% 200 2007 2025 180 Value: 2007: 246 million 160 10.3% DKK 47.7bn 1
Slide 6: Key products continue to drive growth
Conference call 3 August 2007 First six months of 2007 Slide no 5 Key products continue to drive growth – first six months of 2007 Sales as reported Growth analysis Other Norditropin® +2% Local currencies Growth Share of +7% growth 5% 8% Diabetes care Modern insulins 37% 68% NovoSeven® +11% Human in
Slide 7: Modern insulins
Conference call 3 August 2007 First six months of 2007 Slide no 6 Modern insulins Market share of total segment (IMS developed world) Modern insulin sales as reported 50% Levemir® NovoLog® DKK 1.1bn NovoRapid® NovoMix® +79% DKK 3.2bn 40% Levemir® 16% +23% 30% NovoMix® DKK 2.3bn 35% 49% +25% 20% 10%
Slide 8: A continued increase in modern insulin market share
Conference call 3 August 2007 First six months of 2007 Slide no 7 A continued increase in modern insulin market share IMS world modern insulin Modern insulin penetration market shares, volume 80% Novo Nordisk 70% Eli Lilly 60% Sanofi-Aventis 52% 20% Modern insulin 50% 40% 30% Human insulin 20% 10% 0
Slide 9: NovoSeven sales development
Conference call 3 August 2007 First six months of 2007 Slide no 8 NovoSeven® NovoSeven® sales development Key observations • Growth in the second quarter of 1.600 5% in local currencies and : 13 % unchanged as reported 1.400 GR CA 1.200 • North American sales main DKK million contributor to growth 1
Slide 10: Norditropin sales development
Conference call 3 August 2007 First six months of 2007 Slide no 9 Norditropin® Norditropin® sales development Key observations • Growth in the second quarter of 10% in local currencies and 5% 1.000 as reported 900 1 5% 800 GR: • North American sales main CA contributor to growth DKK million 700 600
Slide 11: Sales by region
Conference call 3 August 2007 First six months of 2007 Slide no 10 Sales by region - first six months of 2007 Sales as reported Growth analysis Japan & Oceania -5% Europe Local Growth Share of +7% currencies growth 10% International Europe 7% 19% Operations North America 25% 54% +12% 18% 39% Interna
Slide 12: Levemir reinforces European modern insulin market leadership
Conference call 3 August 2007 First six months of 2007 Slide no 11 Levemir® reinforces European modern insulin market leadership Share of total modern insulin Novo Nordisk’s share of long- sales in Europe acting modern insulin in Europe 25% 23% 80% Novo Nordisk Eli Lilly 70% Sanofi-Aventis 20% 60% 5
Slide 13: US diabetes performance
Conference call 3 August 2007 First six months of 2007 Slide no 12 US diabetes performance Novo Nordisk’s US insulin US insulin market share sales development development Index 80% local currencies 70% Novo Nordisk 600 Eli Lilly 60% Sanofi-Aventis 500 % : 39 50% A GR 400 C 40% 300 30% 200 20% 100 10
Slide 14: Levemir launch in the US
Conference call 3 August 2007 First six months of 2007 Slide no 13 Levemir® launch in the US Levemir® share of total basal modern insulin prescriptions Key observations • Increase in US sales force by 700 7% to 1,900 completed in June 6% • High level of formulary coverage: 5% 80% of total lives at c
Slide 15: Development portfolio – diabetes
Conference call 3 August 2007 First six months of 2007 Slide no 14 Development portfolio – diabetes Compound Type Indication Phase Levemir® Modern insulin Types 1+2 Launched in US, Europe, etc., filed in JP NovoMix® 50 and 70 Modern insulin Types 1+2 Launched in Europe, filed in US Liraglutide GLP-1
Slide 16: Encouraging liraglutide phase 3 data from the LEAD 5 study
Conference call 3 August 2007 First six months of 2007 Slide no 15 Encouraging liraglutide phase 3 data from the LEAD 5 study • Efficacy • More than 50% of patients achieved HbA1c of 7% or lower and more than 35% achieved HbA1c of 6.5% or lower • HbA1c reduction: liraglutide statistically superior t
Slide 17: Development portfolio – haemostasis
Conference call 3 August 2007 First six months of 2007 Slide no 16 Development portfolio – haemostasis Compound Indication Phase NovoSeven® Heat-stable formulation Filed in Europe and US NovoSeven® Trauma Phase 3 NovoSeven® Prophylaxis Phase 2 completed NovoSeven® Spinal surgery (dose escalation) Ph
Slide 18: Development portfolio - other biopharmaceuticals
Conference call 3 August 2007 First six months of 2007 Slide no 17 Development portfolio - other biopharmaceuticals Compound Indication Phase Activelle® low dose Hormone replacement therapy Launched in US, filed in Europe Vagifem® low dose Hormone replacement therapy Phase 3 completed in US, phase 3
Slide 19: Financial results
Conference call 3 August 2007 First six months of 2007 Slide no 18 Financial results DKK million 6M 2007 6M 2006 % change Sales 20,381 18,673 9 Gross profit 15,703 14,006 12 Gross margin 77.0% 75.0% Sales and distribution costs 6,158 5,578 10 Percent of sales 30.2% 29.9% Research and development cos
Slide 20: Currency development
Conference call 3 August 2007 First six months of 2007 Slide no 19 Currency development Spot rates Quarterly average Annual average 640 Annual impact on operating profit of a 5% 620 movement in currency USD/DKK USD DKK 400m 600 USD-related DKK 110m 580 JPY DKK 150m GBP DKK 90m 560 USD-related curren
Slide 21: Outlook 2007
Conference call 3 August 2007 First six months of 2007 Slide no 20 Outlook 2007 • Sales growth expectations: Key currency rates • 11-14% in local currencies DKK 2006 2007 Current per 100 average average rate* • 7-10% as reported USD 595 558 543 • Operating profit growth expectations increased to: JP
Slide 22: Investor information
Conference call 3 August 2007 First six months of 2007 Slide no 21 Investor information Share information Investor Relations Novo Nordisk’s B shares are listed contacts on the stock exchanges in Novo Nordisk A/S Investor Relations Copenhagen and London. Its ADRs Novo Allé, DK-2880 Bagsværd are liste